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The pro-opiomelanocortin (POMC)-derived peptides, a-melanocyte-stimulating hormone, and adrenocorticotropic
hormone, are important mediators of human skin pigmentation via action at the melanocortin-1 receptor. Recent
data suggests that such a regulatory role also exists for the endogenous opiate, b-endorphin (b-END). A role for this
b-END in the regulation of follicular pigmentation, however, has not been determined. This study was designed
to examine the involvement of the b-END/l-opiate receptor system in human follicular melanocyte biology. We
employed RT-PCR, and immunohisto/cytochemistry and immunoelectron microscopy using b-END and l-opiate
receptor speciﬁc antibodies and a functional role for b-END was assessed by direct stimulation with the peptide.
This study has demonstrated that human hair follicle melanocytes (HFM) express mRNA for the l-opiate receptor
and POMC. Furthermore, b-END and its high afﬁnity l-opiate receptor are expressed at the protein level in
glycoprotein100-positive follicular melanocytes and as a function of their anatomic location and differentiation
status during the hair growth cycle. Functional studies revealed that b-END is a modiﬁer of HFM phenotype via its
ability to upregulate melanogenesis, dendricity, and proliferation. These ﬁndings suggest a new regulatory role for
b-END in human HFM biology, providing a new research direction into the fundamental regulation of human hair
pigmentation.
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Human skin is now well recognized to be a local source and
target for pro-opiomelanocortin (POMC)-derived peptides
(Thody et al, 1983; Slominski et al, 1993, 2000b; Wintzen
and Gilchrest, 1996; Slominski and Wortsman, 2000a).
a-Melanocyte-stimulating hormone (a-MSH) and adrenocorti-
cotropic (ACTH) peptides are considered to be important
mediators of human skin pigmentation via action at the
melanocortin-1 receptor (MC-1R) (Lerner and McGuire,
1964; Hunt et al, 1994a, b, c; Suzuki et al, 1996; Wakamatsu
et al, 1997; Tsatmali et al, 1999). In addition to a-MSH and
ACTH, other cleavage products of POMC include b-lipo-
tropic hormone (b-LPH) and the opiate peptide b-endorphin
(b-END) (Benjannet et al, 1991; Seidah et al, 1994). A poten-
tial role for b-END in pigmentation biology has recently been
advanced (Kauser et al, 2003). Pituitary-derived b-END
functions as a potent analgesic, is a mediator of physical
and psychological stress and plays a role in the modulation
of mood, emotion, and behavior (Olson et al, 1986), and
these effects are mediated via both m- and d-opiate
receptors (Gilmore and Weiner, 1989). Recent evidence
suggests that in human epidermis b-END binds specifically
to the m-opiate receptor (m-opiate R) (Bigliardi et al, 1998;
Bigliardi-Qi et al, 2000). In contrast to a-MSH and ACTH, b-
END like other opioids (e.g., the enkephalins and dynor-
phins) exerts its biological effects by inhibition of the
adenylate cyclase pathway and a decrease in the formation
of intracellular cyclic adenosine monophosphate (cAMP)
(Kieffer, 1995).
Several observations suggest a regulatory role for b-END
in human skin pigmentation. Levels of plasma b-END and
b-LPH are increased after UVA exposure, and this has been
associated with increased skin pigmentation in humans
(Levins et al, 1983; Belon, 1985). More recent studies by
Wintzen and et al, however, failed to confirm these findings
after single or repeated exposure to UVA, UVA-1, or UVB
radiation (Wintzen et al, 2001a). Despite this, b-LPH, the
immediate precursor of b-END stimulates melanogenesis
in amphibians and in sheep (Lohmar and Li, 1968) and
elevated serum levels of b-LPH have been associated with
generalized hyperpigmentation in humans (Al Rustom et al,
1986). A regulatory role for b-END in human epidermal
melanocyte (EM) biology has been placed on a firmer
footing by the recent identification of a functionally active
b-END/m-opiate R system in human EM (Kauser et al, 2003).
b-END was shown to be a potent modifier of melanocyte
phenotype by upregulating melanocyte dendricity, prolifera-
tion, and melanogenesis (Kauser et al, 2003).
Abbreviations: ACTH, adrenocorticotropic hormone; a-MSH,
a-melanocyte-stimulating hormone; b-END, b-endorphin; b-LPH,
b-lipotropic hormone; bp, base pair; BPE, bovine pituitary extract;
CT, cholera toxin; d-opiate R, d-opiate receptor; EK, epidermal
keratinocytes; EM, epidermal melanocytes; ET-1, endothelin-1; FP,
follicular papilla; gp100, glycoprotein100; HFK, hair follicle kerati-
nocytes; HFM, hair follicle melanocytes; MC-1R, melanocortin-1
receptor; m-opiate R, m-opiate receptor; ORS, outer root sheath;
PKC, protein kinase C; POMC, pro-opiomelanocortin; TPA, 12-O-
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There is compelling evidence to indicate that POMC-
derived peptides are involved in the regulation of coat color
in certain hairy mammals. In this regard, administration of
a-MSH in mice has been shown to induce coat darkening
by preferentially increasing the synthesis of eumelanin over
pheomelanin in follicular melanocytes (Burchill and Thody,
1986; Burchill et al, 1989). Furthermore, the expression of
POMC, POMC peptides (a-MSH, ACTH, and b-END) and
the MC-1R are confined to specific compartments of the
hair follicle and are modulated during the hair growth cycle
(Slominski et al, 1992, 1996, 1999; Furkert et al, 1997;
Botchkarev et al, 1999). Moreover, their expression is
coupled to early anagen and coincides with the onset of
follicular melanogenesis. Thus, these data implicate POMC
products as regulators of follicular pigmentation/hair cycling
in mice. The role of POMC peptides in the regulation of
human hair follicle pigmentation, however, has received little
attention to date. We have previously shown that the
b-END/m-opiate R system participates in the regulation of
human skin pigmentation (Kauser et al, 2003). By extension,
it is also possible that a similar situation may exist in the
modulation of human hair pigmentation.
This study examines the involvement of the b-END/m-
opiate R system in follicular melanocytes in vitro and in situ
during the hair growth cycle. We present evidence that this
opiate/receptor system is differentially expressed in hair
follicle melanocytes (HFM) as a function of their anatomic
location and activity within the hair follicle and also during
the hair growth cycle. In addition, b-END is involved in the
regulation of several melanocyte phenotypic traits including
dendricity, proliferation, and pigmentation in HFM. Thus,
b-END may be considered as a potential melanotropin in
hair follicle pigmentation biology.
Results
Hair follicle melanocytes express l-opiate receptor and
POMC mRNA in vitro RT-PCR with primers specific for
m-opiate R produced amplification products of the expected
size of 433 bp in normal human follicular melanocytes,
keratinocytes, and FP fibroblasts (Fig 1A). As b-END is a
cleavage product of POMC, the expression of the POMC
message was also analyzed in cultured HFM, HFK, and FP
fibroblasts and produced the expected 260 bp product
specific for exon 3 of the POMC mRNA (Fig 1B). Both bands
for POMC and m-opiate R were discrete and reproducible,
and used the precise primer pairs confirmed in previously
published protocols of Slominski et al (1995) and Bigliardi
et al (1998). The PCR products produced were sequenced
in these studies. Amplification of RNA samples that were
not reverse transcribed and samples from which cDNA was
omitted from the reaction mixture were also subjected to
PCR. These negative controls did not reveal a specific
product (Fig 1A,B). Thus, cultured HFM express mRNA for
both POMC and the m-opiate R.
b-END/l-opiate receptor expression in human follicular
melanocytes is modulated during the hair growth
cycle The expression of b-END peptide was prominent in
the hair bulb and outer root sheath (ORS) of anagen VI hair
follicles but was strikingly absent from the FP. Dendritic cells
located in the melanogenic zone of the hair bulb, that is,
above and around the upper pole of the FP, and in the ORS
showed marked b-END immunoreactivity. The melanocytic
identity of these b-END-positive cells was confirmed by
double immunolabelling with antibodies against the mela-
nocyte lineage-specific marker, gp100, and b-END (Fig 2A).
During catagen, by contrast, b-END immunoreactivity
became detectable in the FP, and was retained in the epi-
thelium of the former bulb region. A weaker and more diffuse
expression pattern was evident in the regressing epithelial
strand of catagen hair follicles. Double immunolabelling with
gp100 and b-END revealed expression of b-END in rare
non-dendritic melanocytes located in the former bulbar area
at the extremity of the epithelial strand (Fig 2B). When
human scalp hair follicles progressed to telogen the
expression of b-END became prominent in the epithelial
sac and was somewhat reduced in the secondary germ.
Melanocytes in the peripheral regions of the epithelial sac
and in the secondary germ showed strong b-END immu-
noreactivity throughout telogen (Fig 2C).
The m-opiate R was prominently expressed in the ORS
and the hair bulb matrix of anagen VI hair follicles. Strikingly,
and in contrast to b-END expression m-opiate R was
strongly expressed in the FP of anagen VI hair follicles.
m-Opiate R co-localized strongly with a minor sub-population
of dendritic gp100-positive melanocytes located in the
proximal and peripheral regions of the hair bulb matrix and
with gp100-positive melanocytes located in the ORS of the
follicle as demonstrated by double immunolabelling using
gp100 and m-opiate R-specific antibodies, interestingly,
m-opiate R expression was not detectable in the major bulbar
melanocyte population, namely, the cells in the melano-
genic zone (Fig 3A). The expression of m-opiate R became
weaker and rather diffuse in the regressing epithelial strand
of catagen hair follicles, compared with the strong receptor
expression that was restricted to the epithelium surrounding
the developing club and FP of late catagen hair follicles.
Non-dendritic melanocytes located in the former bulbar
area at the extremity of the epithelial strand exhibited
Figure1
Detection of l-opiate receptor and POMC-specific transcripts by
RT-PCR in cultured follicular melanocytes, keratinocytes and
follicular papilla fibroblasts. Detection of a 433 bp product specific
for m-opiate R (A), detection of a 260 bp product specific for POMC (B).
(A) Lane 1: DNA ladder, Lane 2: HFM, Lane 3: HFK, Lane 4: FPF, Lane 5:
EK, Lane 6: negative control #1, omission of cDNA, Lane 7: negative
control #2, substitution of cDNA with total RNA. (B) Lane 1: DNA ladder,
Lane 2: HFM, Lane 3: HFK, Lane 4: FPF, Lane 5: plasmid containing
POMC gene, Lane 6: negative control #1, omission of cDNA, Lane 7:
negative control #2, substitution of cDNA with total RNA.
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marked m-opiate R expression, similar to melanocytes
located in the epithelium surrounding the telogen club
(Fig 3B). m-Opiate R expression was observed throughout
the epithelial sac in telogen hair follicles and was particularly
marked in individual cells located in the mid-peripheral
regions. The melanocytic nature of these m-opiate R-posi-
tive cells was identified by double immunolabelling using
m-opiate R and gp100-specific antibodies (Fig 3C). The
omission of both primary antibodies but inclusion of
secondary antibodies did not produce any specific staining
(data not shown). Thus, these results show that the b-END/
m-opiate R system is differentially expressed in the hair
follicle, and its complement of melanocytes, during the hair
growth cycle in situ. By contrast, expression of the d-opiate
R (a second, though weak-affinity, receptor for b-END) was
not detected in either melanocytes or keratinocyte popula-
tions of the epidermis or hair follicle both in situ and in vitro
(data not shown). d-Opiate R expression, however, was
detected elsewhere in human skin (e.g., eccrine sweat
glands) and also in vessels of murine heart, employed as a
positive control.
b-END and l-opiate receptor are differentially expressed
in pigmented bulbar and amelanotic hair follicle mela-
nocytes b-END was differentially expressed in isolated
cultured amelanotic and melanotic human scalp hair bulb
melanocytes, with immunoreactivity seen throughout the
cell body but with a prominent granular staining pattern
observed in the peri-nuclear and nuclear regions of
amelanotic cells. By contrast, b-END expression was much
reduced or lost from the highly melanized dendrites of
pigmented bulbar melanocytes and was instead restricted
in a granular pattern to the peri-nuclear and nuclear regions
of these pigmented melanocytes (Fig 4A1,A2). These
findings are consistent with b-END expression detected
in situ, where strong expression was also detected in the
melanogenic zone of anagen VI hair follicles. By contrast,
the expression of m-opiate R was significantly down-
regulated in pigmented bulbar melanocytes, with weak
expression seen only in the peri-nuclear region of these
cells. This is in agreement with m-opiate R expression
detected in situ, where melanocytes located in the melano-
genic zone of anagen VI hair follicles were negative for
m-opiate R immunoreactivity. m-Opiate R expression was
higher in amelanotic melanocytes compared with melanotic
bulb-derived melanocytes and was distributed in a rather
diffuse granular staining pattern throughout the cell body
and nucleus (Fig 4B1,B2).
Figure 2
Human hair follicle melanocytes express b-
END during the hair growth cycle. Anagen: b-
END expression was high in bulbar and ORS
melanocytes (arrowheads) (A). Catagen: b-END
immunoreactivity was detected in rare melano-
cytes of the former bulb matrix (arrowhead) (B).
Telogen: b-END expression was observed in
melanocytes of the epithelial sac and also those
in the secondary germ (arrowheads) (C). b-END:
red, gp100: green; co-localization: yellow. Scale
bar: 50 mm. C: club, ESt: epithelial strand, ESa:
epithelial sac, SG: secondary germ.
Figure 3
Human hair follicle melanocytes express the
l-opiate receptor during the hair growth
cycle. Anagen: m-opiate R expression was
detected in a minor sub-population of melano-
cytes located in the proximal/peripheral matrix
region and also in the ORS (arrowheads), but was
low/absent in melanocytes of the melanogenic
zone (A). Catagen: m-opiate R immunoreactivity
was high in melanocytes in the regressing
epithelial strand, above the FP and in a popula-
tion of melanocytes located in the epithelial sac
surrounding the forming club (arrowheads) (B).
Telogen: small numbers of m-opiate R-positive
melanocytes were observed in the epithelial sac
(arrowheads) (C). m-Opiate R: green, gp100: red;
co-localization: yellow/orange. Scale bar: 50 mm.
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Figure 4
Human follicular melanocyte primary cultures express b-END and the l-opiate receptor. Each frame pair represents the same cell population
taken with both fluorescence and bright-field microscopy (e.g., A1, A2). Variable expression of b-END (A1) and the m-opiate R (B1) was present in
HFM primary cultures. b-END expression was confined to the peri-nuclear region in pigmented bulbar melanocytes (arrowhead). In amelanotic
melanocytes it was diffusely expressed throughout the cell body (arrow) (A1, A2). High m-opiate R expression was detected in proliferative
amelanotic melanocytes (arrow) but was downregulated in pigmented bulbar melanocytes (arrowhead) (B1, B2). Gp100 expression in both
amelanotic (arrow) and pigmented bulbar melanocytes (arrowhead) confirmed melanocyte identity (C1, C2). Negative control from which the primary
antibody was replaced by pre-immune serum from secondary antibody host (D1, D2). Scale bar: 17 mm.
Figure 5
Cultured follicular melanocytes, follicular keratinocytes and follicular papilla fibroblasts express b-END and the l-opiate receptor. The
expression of b-END (A) and m-opiate R (B) was variable in cultured HFM at passage 4. Expression was higher in differentiated cells (arrowhead) than
in undifferentiated cells (arrow) being strongest in the peri-nuclear region. Strong b-END immunoreactivity was also evident in granular structures
associated with the nucleus (solid arrowhead) (A). b-END immunoreactivity in HFK (passage 2) was marked in more differentiated keratinocytes
(arrowhead) than in basal keratinocytes (arrow), and was confined to the peri-nuclear region of these cells (C). Expression of m-opiate R in HFK was
stronger in basal keratinocytes (arrow) compared with more differentiated keratinocytes (arrowhead) (D). b-END expression in FP fibroblasts was
restricted to a sub-population and exhibited a granular distribution pattern (arrowhead). Weaker expression was observed in other cells (arrow) (E).
m-Opiate R immunoreactivity was also variable in FP fibroblasts (arrowhead), where marked peri-nuclear expression was evident in a sub-population
of cells (F). Negative controls from which the primary antibody was replaced by pre-immune serum from secondary antibody host (G, H). Scale bar:
17 mm.
Figure 6
Stimulation of hair follicle melanocyte dendricity after incubation with b-END. HFM cultures (passage 2–5) were established in bFGF/ET-1
(n¼ 4) or TPA/CT (n¼3)-supplemented medium. Cells that were established in the latter medium type were switched to bFGF/ET-1-supplemented
medium for 8 d prior to commencing with experiments. A marked increase in cell dendricity was seen 72 h after b-END stimulation in melanocytes
derived from brown hair (A1, A2) and black hair (B1, B2). Follicular melanocytes (derived from brown hair) that were established in TPA/CT-
supplemented medium showed a striking reduction in cell dendricity after b-END stimulation (C1, C2). Scale bar: 50 mm.
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The positive gp100 staining in both amelanotic and
melanotic melanocytes confirmed their melanocyte identity
and also verified that the downregulation of m-opiate R
expression observed in pigmented bulbar melanocytes was
not due to the quenching of fluorescence by the high levels
of melanin in these cells (Fig 4C1,C2). The omission of the
primary antibody did not result in any staining (Fig 4D1,D2).
To determine whether the expression of the b-END/m-
opiate R system was retained with progressive passaging in
our HFM in vitro model, expression of the above markers
was examined at passage 4 (Fig 5A,B). A positive correla-
tion between b-END expression and cell differentiation
status was detected; the more differentiated melanocytes
(i.e., more dendritic and less proliferative) showed stronger
b-END immunoreactivity compared with less differentiated
(i.e., less dendritic and with greater proliferative potential)
cells (Fig 5A). The phenotypic criteria used for assessing
melanocyte differentiation status were based on those
previously described (Bennett et al, 1985). Similarly, the
expression of m-opiate R also correlated positively with
melanocyte differentiation status. A slightly altered expres-
sion pattern was observed at later passage (4) where strong
plasma membrane immunoreactivity was evident in differ-
entiated melanocytes only (Fig 5B). These results demon-
strate that b-END and m-opiate R are differentially
expressed in melanotic bulb melanocytes and amelanotic
ORS/matrix melanocytes and that expression of these
peptides is retained with passage.
b-END and l-opiate receptor are expressed in cell sub-
populations derived from different hair follicle compart-
ments b-END expression was also marked in the peri-
nuclear region of differentiating keratinocytes (Fig 5C). In
contrast to follicular melanocytes, granular staining was not
observed in keratinocyte nuclei. A similar pattern was
observed for m-opiate R immunoreactivity, which was again
prominent in the peri-nuclear region of those keratinocytes
with a basal cell phenotype. Expression was weaker and
more diffuse in more differentiated cells (Fig 5D). Keratino-
cyte identity was confirmed by positive staining with the
anti-hair follicle keratin-specific antibody, AE13 (data not
shown). The phenotypic criteria used for assessing kerati-
nocyte differentiation were based on the following; basal
cells were categorized as those cells, which were small,
non-granular, and closely packed with a cobble-stone-like
morphology and were highly proliferative. Differentiating
keratinocytes were more englarged, pleomorphic shaped,
undergo stratification, and have limited proliferative poten-
tial (Holbrook and Hennings, 1983). A similar heterogeneous
pattern of b-END and m-opiate R expression was detected
in fibroblast-like cells derived from the FP. b-END was
weakly and diffusely expressed throughout the cytoplasm in
most cells, though a sub-population exhibited strong
expression in distinct granular structures within the cyto-
plasm and again also in the nucleus (Fig 5E,F). No staining
was detected in the negative controls where the primary
antibody had been omitted (Fig 5G,H). Thus, these results
indicate that follicular keratinocytes and FP fibroblasts
express b-END and m-opiate R in vitro at the protein level
and that the expression level and pattern of these peptides
appears to be associated with cell differentiation status.
b-END modulates hair follicle melanocyte dendricity in
vitro The functional significance of the in situ and in vitro
detection of the b-END/m-opiate R system in HFM was
assessed by determining the effects of b-END stimulation
on the phenotype of follicular melanocytes. Prior to b-END
stimulation HFM established in bFGF/ET-1-supplemented
medium exhibited a predominately bipolar morphology with
occasional tripolar cells (Fig 6A1,B1). By contrast, melano-
cytes established in TPA/CT-supplemented medium and
then switched to bFGF/ET-1-containing medium for 8 d
prior to experiments retained their multiple dendrites (Fig
6C1). Stimulation with b-END (108 M) increased cell
dendricity in four of seven HFM lines examined and was
seen only in cell lines that had been established in bFGF/ET-
1-supplemented medium (Fig 6A2,B2). The induced effects,
however, were variable across cell lines. The extent of
b-END stimulation of dendricity appeared to correlate with
hair color of cell donors, b-END produced the greatest
increase in dendricity in melanocytes derived from darker
haired individuals (Fig 6B2). By contrast, b-END produced a
marked reduction in cell dendricity in melanocyte lines that
had been established in TPA/CT-supplemented medium
and then switched to bFGF/ET-1-supplemented medium
(Fig 6C2). Interestingly, these effects appeared to be HFM
specific, as they were not observed with matched EM lines
(data not shown). Thus, exogenous b-END can significantly
increase dendricity in HFM cultures established in medium
containing natural melanocyte mitogens (bFGF/ET-1), but
reduces dendricity in cells originally established in medium
containing artificial melanocyte mitogens (TPA/CT).
b-END stimulates melanogenesis and proliferation in
hair follicle melanocytes in vitro Studies on the melano-
genic and proliferative effects of b-END stimulation on HFM
cultures derived from individuals with hair colors ranging
from light-brown to black, showed that b-END significantly
increased melanogenesis in all cell lines tested (n¼7)
po0.001 (Fig 7A, Table I). The effects were variable
between cell lines and ranged from 9.5% to 35.7% with
an average increase of 24.1% and SEM of 3.6% above
control unstimulated levels (Table I). The melanogenic
effects of b-END appeared to be correlated with hair color
of the donor. Melanocyte lines derived from dark-haired
individuals (i.e., dark-brown and black) were most res-
ponsive to b-END stimulation (Table I). Unlike the effects
of b-END on follicular melanocyte dendricity, HFM lines
established in TPA/CT-supplemented medium also re-
sponded to b-END stimulation with an increase in melano-
genesis (Fig 7A2, Table I), and these increases were
comparable with HFM lines that had been established
in bFGF/ET-1-supplemented medium. Visible increases in
melanogenesis were evident in stimulated cell pellets of
cell lines that had low basal melanin levels (Fig 7A1,A2). This
was less apparent in HFM lines with high basal levels of
melanin (Fig 7A3).
Evaluation of cell proliferation showed a significant
increase in HFM number with b-END stimulation in all cell
lines examined (n¼ 7) po0.001 (Fig 7B, Table II). As with
melanogenesis, the effects of b-END on HFM proliferation
were also variable. The b-END induced increase in cell num-
ber ranged from 7.4% to 29.0% with an average increase of
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18.1% and SEM of 3.3% above control unstimulated levels
(Table II). The mitogenic effects of b-END in HFM lines
that were established in TPA/CT-supplemented medium
were similar to cell lines that were established in medium
supplemented with bFGF/ET-1 medium. Based on the
above in vitro results b-END has significant melanogenic
and mitogenic effects on HFM.
b-END and l-opiate receptor expression co-localizes on/
in melanosomes in cultured hair follicle melanocytes To
determine the precise location/distribution of b-END and
m-opiate R in melanocytes immunoelectron microscopy was
performed on cultured HFM. Results revealed a close
association of b-END expression with melanosomes. b-END
labelling was confined predominately, but not exclusively to
less mature melanosomes of stage II and III, which repre-
sent early stages of active melanogenesis (Fig 8A). Similar-
ly, m-opiate R labelling was also predominately present in
pre-melanosomes, but occasionally also associated with
mature melanosomes (Fig 8B). These observations indicate
a specific association of b-END and its receptor on/in
melanosomes in cultured follicular melanocytes.
Discussion
In this study, we have demonstrated for the first time the
existence of the b-END/m-opiate R system in human HFM at
both the message and protein levels that this signalling
system is expressed in follicular melanocytes as a function
of their anatomic location and differentiation status during
the hair growth cycle, and that b-END is a potent modifier of
follicular melanocyte phenotype via its ability to stimulate
Figure 7
Stimulation of melanogenesis and proliferation in follicular mela-
nocytes after incubation with b-END. Melanin content was deter-
mined spectrophotometrically (475 nm) after sodium hydroxide
solublization. Cells with low basal melanin levels showed visible
increases in melanogenesis after b-END stimulation (A1, A2). This
visible change was not appreciable in cells containing high basal
melanin levels (A3). Cell proliferation was assessed by determining cell
counts before and after b-END stimulation. Results are expressed as a
percentage increase in melanin content (A) and cell number (B) over
control unstimulated levels and are a mean  SEM of seven cell lines.
po0.001.
Table I. Effect of b-END stimulation on melanin content in
cultured hair follicle melanocytes
Cell line
PST/HC
Control
melanin
content
(pg/cell)
b-END (108 M)
melanin
content
(pg/cell)
Percentage
increase
in melanin
content
1. III/light-brown 20.0 21.9 þ 9.5
2. III/mid-brown 23.3 27.7 þ18.9
3. III/brown 28.1 35.5 þ26.3
4. III/brown 32.6 38.0 þ16.6
5. III/brown 7.6 9.7 þ27.6
6. IV/dark-brown 40.1 53.7 þ33.9
7. V/black 48.4 65.7 þ35.7
Mean percentage increase  SEM þ24.1  3.60
Statistical significance po0.001
Increases in melanin content are expressed as a percentage increase
over control (unstimulated) levels for each cell line (1–7). HFM cultures
established in TPA/CT supplemented medium, which were then switched
to bFGF/ET-1 supplemented medium for 8 days prior to b-END stimu-
lation (lines 1,2,5).
Statistical significance was assessed by Student’s paired t-test.
po0.001.
SEM, standard error of the mean; PST, photo skin type; HC, hair color.
Table II. Effect of b-END stimulation on cell number in
cultured hair follicle melanocytes
Cell line
PST/HC
Control
cell
number
103
b-END
(108 M)
cell
number 103
Percentage
increase
in cell
number
1. III/light-brown 222.0 238.5 þ 7.4
2. III/mid-brown 108.0 121.5 þ 12.5
3. III/brown 129.0 165.0 þ 27.9
4. III/brown 426.0 474.0 þ 11.3
5. III/brown 115.5 144.0 þ 24.7
6. IV/dark-brown 162.0 184.5 þ 13.9
7. V/black 139.5 180.0 þ 29.0
Mean percentage increase  SEM þ 18.1  3.34
Statistical significance po0.001
Increases in cell number are expressed as a percentage increase over
control (unstimulated) levels for each cell line (1–7). Shaded areas
highlight HFM cultures established in TPA/CT supplemented medium,
which were then switched to bFGF/ET-1 supplemented medium for 8
days prior to b-END stimulation (lines 1,2,5).
Statistical significance was assessed by Student’s paired t-test.
po0.001.
SEM, standard error of the mean; PST, photo skin type; HC, hair color.
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melanogenesis, dendricity, and proliferation in these cells.
Thus, these findings suggest an important new regulatory
role for b-END in human HFM biology.
In this study, we present evidence that b-END and its
high affinity m-opiate R are expressed at the mRNA level in
human follicular melanocytes, keratinocytes, and FP fibro-
blasts (Fig 1A,B). These findings are in agreement with the
detection of POMC mRNA in neonatal foreskin epidermis
(Slominski et al, 1995) and dermis (Schiller et al, 2001). The
expression of the b-END peptide in human follicular cells
has been controversial. Slominski et al reported b-END
immunoreactivity in keratinocytes of the hair bulb matrix
and the ORS in scalp but not truncal skin (Slominski et al,
1993). More recently, however, prominent b-END immuno-
reactivity has been reported in the follicular matrix of truncal
skin (Wintzen et al, 2001b). These inconsistencies could be
due to the different fixation protocols employed but also
suggest possible regional variations in b-END expression in
human skin. These studies, however, make no specific
reference of b-END immunoreactivity in melanocytes.
We report here that differential b-END expression occurs
as a function of melanocyte location and differentiation
status within full anagen (VI) hair follicles. b-END immuno-
reactivity is more pronounced in melanogenically active
bulbar melanocytes compared with amelanotic ORS mela-
nocytes. Furthermore, b-END expression, although marked
in the epithelial compartments, is conspicuously absent
from the FP mesenchyme (Fig 2A), suggesting that this
mesenchymal component may not participate directly in
b-END production during anagen VI. b-END immunoreac-
tivity, however, is detected in the FP during catagen and
telogen, as well as in the hair follicle epithelium. In this way,
a reduction in FP b-END levels during anagen runs contrary
to the usual pattern of hair cycle-dependent fluctuations in
other growth factors (reviewed in Stenn and Paus, 2001).
Although b-END immunoreactivity is low in the rare non-
dendritic melanocytes in catagen follicles (Fig 2B), expres-
sion of this neuropeptide is increased in those ‘‘resting’’
melanocytes distributed in the peripheral regions of the
epithelial sac in telogen follicles (Fig 2C). The striking
upregulation of b-END expression in melanogenically active
bulbar melanocytes during anagen VI, however, strongly
suggests that HFM are an important local source of this
POMC peptide at this stage of the hair cycle, and that
b-END may play an important role in the regulation/main-
tenance of human hair follicle pigmentation. This pattern
of b-END expression appears to be species-specific, as
b-END immunoreactivity in murine skin was found to be
confined to the sebaceous glands throughout the hair
growth cycle (Furkert et al, 1997).
The expression of the m-opiate R also exhibits hair cycle-
dependent fluctuations. But in marked contrast to b-END,
expression of the receptor is detected during anagen VI only
in a small sub-population of weakly melanogenic melano-
cytes located both in the proximal/peripheral hair bulb
matrix and in amelanotic ORS melanocytes. The FP, hair
bulb matrix keratinocytes, and ORS also exhibit strong
m-opiate R expression (Fig 3A). The latter observation concurs
with the findings of Bigliardi and et al who also reported
m-opiate R immunoreactivity in human hair follicle ORS
(Bigliardi et al, 1998). The absence of m-opiate R detection in
melanogenically active bulbar melanocytes was striking and
could be due to low levels of receptor availability for the
anti-m-opiate R antibody due to ligand–receptor saturation.
Alternatively, m-opiate R expression may indeed be down-
regulated, as appears to be the case in catagen (Fig 3B) and
in telogen follicles (Fig 3C).
The m-opiate R is also expressed throughout the FP and
follicular epithelium. Thus, the presence of the b-END ligand
and m-opiate R in both follicular melanocytes, keratinocytes,
and FP fibroblasts suggests that autocrine and paracrine
effects may regulate follicular melanocyte behavior during
catagen and telogen only, as in situ studies failed to detect
b-END immunoreactivity in the FP of anagen VI hair follicles.
b-END expression, however, was detected in some isolated
FP cells under in vitro conditions. These observations are
in agreement with the detection of POMC, POMC-derived
peptides as well as PC1 and PC2 in cultured human dermal
fibroblasts (Schiller et al, 2001). The absence of b-END
expression in anagen VI FP situ and the detection of the
peptide under in vitro conditions could be due to variable
peptide levels dependent on cell differentiation status or
due to the different detection systems employed for the
in situ versus in vitro assays. Furthermore, FP fibroblasts are
a relatively stable cell population in vivo (Tobin et al, 2003) in
contrast to their induced proliferation status under in vitro
conditions which may upregulate the expression of b-END
in these cells.
Figure 8
b-END and l-opiate receptor expression co-localizes in/on melanosomes in cultured hair follicle melanocytes. b-END labelling was confined
predominately to the outer membrane of stage II and III melanosomes (arrowheads). The labelling was weaker in stage IV melanosomes (A). The
framed areas within main images indicate the origin of inserts (Ai) and (Aii). m-Opiate R labelling was detected most commonly in pre-melanosomes
but was also occasionally associated with more mature melanosomes (arrowheads) (B). The framed areas indicate the origin of inserts (Bi) and (Bii).
No gold labelling was seen in the negative control incubated only with the gold-conjugated secondary antibody (C). Scale bar: 3 mm.
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b-END exhibits high affinity binding to the m-opiate R but
only weak binding to the d-opiate R (Gilmore and Weiner,
1989). Moreover, recent data suggest that wild-type
d-opiate R is present in normal human melanocytes, but
only at the message level (Mayer et al, 2000). Protein express-
ion or functional activity was not reported in this study. We
were also unable to detect the d-opiate R protein in either
epidermal or follicular melanocytes and keratinocytes
in situ or in vitro.
A major focus of this study was to examine the involve-
ment of the b-END/m-opiate R system in the regulation of
human HFM biology. POMC peptides, a-MSH, and ACTH
are considered to be important regulators of follicular
pigmentation/hair cycling in mice (Burchill and Thody,
1986; Burchill et al, 1989; Botchkarev et al, 1999; Slominski
et al, 1999). Immunocytochemical detection of the b-END/
m-opiate R system in HFM primary cultures (which consist of
both terminally differentiated bulbar melanocytes that are
actively engaged in melanogenesis and also amelanotic
melanocytes) demonstrates that strong b-END immunor-
eactivity that is restricted to the peri-nuclear region of
pigmented melanocytes but is reduced/lost from the high-
ly melanized dendrites of these cells (Fig 4A1,A2). This
distribution pattern suggests that b-END expression may be
associated with early stages in melanosome biogenesis,
further supported by our immunoelectron microscopic
observations that revealed a close association between
b-END and m-opiate R expression primarily in less mature
stage II and III melanosomes (Fig 8A,B). This finding
concurs with our recent detection of this opiate and
receptor system in human epidermal melanosomes (Kauser
et al, 2003) and with earlier studies that localized MSH in
pre-melanosomes (Lerner et al, 1979), and those that
suggest the existence of internal binding sites for MSH in
vesicular structures (Orlow et al, 1990; Chakraborty et al,
1991). Furthermore, we have previously shown that the full
POMC processing system is present in human melano-
somes (Peters et al, 2000). Thus, our current detection of
the b-END and m-opiate R system in melanosomes
suggests the possibility of internalization of the receptor/
ligand complex into the melanosome and in this way may
facilitate intra-melanosomal regulation and subsequent
melanogenesis.
The positive correlation between b-END/m-opiate R
expression and melanocyte differentiation status in culture
(passage 4) (Fig 5A,B) suggests an autocrine control of
melanocyte function by this system. Given that the b-END
and the m-opiate R are only co-expressed in relatively
undifferentiated melanocytes of the ORS and the proximal/
peripheral matrix, b-END/m-opiate R signalling may partici-
pate particularly in the biology of these undifferentiated
melanocytes. For example, b-END/m-opiate R signalling
may be involved in their migration into the hair matrix and
then their subsequent differentiation into pigment-produ-
cing cells. In support of this, recent studies have shown that
exogenously supplied b-END stimulates migration of cul-
tured human foreskin keratinocytes (Bigliardi et al, 2002).
Amelanotic melanocytes are also found in the ORS of white
hair follicles (Takada et al, 1992; Horikawa et al, 1996) and it
has been speculated that the whitening of hair with
advancing age is a consequence of yet unknown factors
that prevents immature melanocytes from migrating or
maturing into pigment producing cells (Tobin and Paus,
2001). Age-related changes in b-END homeostasis within
the hair follicle pigmentary unit could conceivably play a
significant role in the onset of hair graying and this is
currently under investigation.
In addition to describing the full expression of the b-END/
m-opiate R system, we also provide direct evidence for the
existence of a fully active b-END/m-opiate R system in
human HFM. Exogenously supplied b-END stimulates
increased melanogenesis and proliferation in follicular
melanocyte cultures and these effects were comparable
with those observed with b-END (Kauser et al, 2003),
a-MSH and ACTH (Hunt et al, 1994c) stimulation of EM.
Although a-MSH and ACTH but not b-END have been
shown to be melanogenic in B16F1 melanoma cells (Lunec
et al, 1992), data from this study suggest a pigmentary role
for this opiate in normal human follicular melanocytes.
These findings may suggest species-specific modulatory
roles for b-END, but importantly shows that data from rodent
melanoma cell lines should be interpreted with caution since
these cells are not subject to normal regulatory systems.
The only opiate receptor thus far shown to have growth
factor activity is the z-opiate receptor (Zagon et al, 1996; Wu
et al, 1998). We have previously shown that the m-opiate
R ligand, b-END has significant mitogenic effects on EM
(Kauser et al, 2003) and now also here in follicular
melanocyte cultures. The increase in cell number detected
in b-END-stimulated cultures does not appear to be due to
the inhibition of apoptosis, as dead (i.e., floating) cells were
not evident in either control or stimulated cultures. Thus, the
greater cell numbers in b-END stimulated cultures can only
be interpreted as resulting from their enhanced proliferation.
The melanogenic effects of b-END stimulation in follicular
melanocytes appeared to correlate with hair color. HFM
derived from dark-haired individuals (dark-brown and black)
were the most b-END responsive compared with lighter hair
color (Table I). Donor variability in EM responsiveness to
a-MSH and ACTH stimulation is thought to reflect differ-
ences in the extent of peptide binding to the MC-1R and its
subsequent signalling activity (Hunt et al, 1994c; Hunt et al,
1996). Such control points may also exist in m-opiate R
signalling in follicular melanocytes. b-END also exhibits
potent dendritogenic effects in HFM cultures and were
greater in melanocytes derived from dark-haired individuals
(Fig 6B1,B2). Successful transfer of melanosomes depends
both on the number of dendrites per cell and their length.
Both of these parameters are upregulated by b-END.
Therefore stimulated melanocytes not only produce more
highly melanized pigment granules but they can potentially
transfer these more effectively to recipient keratinocytes.
Interestingly, HFM cultures that had been established
initially in TPA/CT-supplemented medium, but then switched
to natural mitogen (ET-1/bFGF) containing medium, showed
a marked reduction in cell dendricity in response to b-END
stimulation (Fig 6C1,C2), despite the induction of melano-
genesis (Fig 7A, Table I). The inclusion of artificial mitogens
such as TPA in the culture medium is thought to down-
regulate MC-1R expression on EM rendering them unre-
sponsive to a-MSH (Halaban et al, 1983; Ranson et al, 1988;
Friedmann et al, 1990). Our findings suggest that TPA/CT
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may also affect m-opiate R function in HFM by effecting
receptor expression and/or b-END/m-opiate R interaction
and subsequent signal transduction. To further dissect this
possibility, receptor-binding studies to characterize the
pharmacological properties of m-opiate R are currently
under investigation in our laboratory. Although the signalling
pathways involved in melanogenesis stimulation appear to
be unaffected by prior exposure of melanocytes to TPA/CT,
those inducing cell dendricity seem to be inhibited. This
suggests that the melanogenic and dendritogenic respon-
ses to b-END are likely to be independent of one another.
TPA is a known activator of protein kinase C (PKC) and PKC
has considerable effects on cell proliferation and cell
spreading. Thus, our data reinforces the critical importance
of culture conditions in melanocyte research. Furthermore,
recent evidence suggests that b-END can act as a growth
factor for other neural crest-derived cells, for example,
hippocampal progenitors and this growth stimulation may
be mediated via ERK1/2 activation (Persson et al, 2003).
Thus, b-END may stimulate follicular melanocyte prolifera-
tion via a similar pathway.
Melanocortins induce melanogenesis by activating pre-
dominately the cAMP second messenger system (Burbach
and Weigant, 1990; Busca and Ballotti, 2000). By contrast,
b-END, like other opioids, mediate their biological actions
by the inhibition of this signalling pathway (Kieffer, 1995).
m-Opiate R agonists are known to activate PKC (Liu and
Anand, 2001). PKC-b-dependent pathways are increasingly
being implicated in the regulation of melanogenesis (Park
et al, 1993). Moreover, it has been recently reported that the
major transcription factor for tyrosinase, microphthalmia-
associated transcription factor, regulates PKC-b transcrip-
tion.1 Our previous findings (Kauser et al, 2003) and the
current study suggest that the melanogenic and mitogenic
effects of b-END/m-opiate R interaction could operate via
PKC signalling systems. It has been shown that ligands for
m-opiate R, for example, enkephalins, can stimulate the
phosphorylation of ERK in a PKC-dependent manner. This
may represent a second potential pathway for b-END
effects on PKC signalling (Belcheva et al, 2001). In support
of this the topical application of the selective PKC inhibitor
bisindolylmaleimide reduces hair length (presumably via
anagen truncation) and calibre (presumably via alteration of
keratinocyte proliferation/differentiation) in guinea pigs and
mice in vivo (Park et al, 2004). Since PKC may be implicated
in keratinocyte differentiation (Lee et al, 1998), together with
higher levels of b-END expression detected in more
differentiated keratinocytes, we would like to propose that
b-END may also play an important role in the modulation of
hair growth/cycling. In this way, it is of note that significantly
higher plasma b-END levels have been reported in obese
hirsute women (Ruutiainen et al, 1985), where increased hair
growth reflects lengthened anagen and increased hair
pigmentation.
In conclusion, these findings propose an important new
role for b-END in the biology of human hair pigmentation.
These data offer to provide a new research direction into the
mechanisms that regulate human hair pigmentation where
POMC peptides could play a major role. The manipulation
of such mechanisms could offer the possibility of altering
hair color or indeed reversing the process of hair graying.
Materials and Methods: Isolation and Culture of
Hair Follicle Cell Sub-Populations
Hair follicle melanocytes Normal human haired scalp tissue was
obtained with informed consent after elective plastic surgery from
seven females (age range 43–62 y, mean age 52 y, hair color light-
brown to black). Local ethics committee approval was obtained for
this study. All cell culture reagents were obtained from Invitrogen
Ltd (Invitrogen Ltd, Paisley, Scotland) unless otherwise stated. The
skin samples were collected in RPMI 1640 medium and were
processed within 5 h (hours) of surgery.
HFM cultures were established essentially as described by
Tobin et al (1995). Briefly, scalp specimens were cut into 1 cm2
pieces and the epidermis and upper 1 mm of dermis were carefully
removed with a scalpel. Hair follicles were isolated by incubating
the tissue in Eagle’s minimal essential medium (EMEM) with Earle’s
salts and glutamax-L supplemented with 10% FCS, 200 U per mL
penicillin and 200 mg per mL streptomycin, 5 mg/mL fungizone, and
0.5% collagenase type V (Sigma, Poole, Dorset, UK). The released
hair follicles were washed repeatedly with PBS until hair follicles
appeared pure by microscopic examination. Single cell suspen-
sions were obtained by treatment with 0.05% trypsin and 0.53 mM
ethylenediamine tetraacetic acid (EDTA) for 5–10 min at 371C.
HFM cultures were established using media supplemented
with either artificial mitogens or natural melanocyte mitogens as
follows. Artificial mitogen medium was EMEM supplemented with
2% FCS,  1 concentrated non-essential amino acid mixture, 100
U per mL penicillin and 100 mg per mL streptomycin and 2 mM
L-glutamine, 50 nM 12-O-tetradecanoylphorbol-13-acetate (TPA)
(Sigma, Poole, Dorset, UK), and 1 nM cholera toxin (CT) (ICN
Biomedicals Inc, Ohio). Natural mitogen medium was EMEM with
all the above supplements except for TPA and CT; these were
replaced by 5 ng per mL endothelin-1 (ET-1) and 5 ng per mL basic
fibroblast growth factor (bFGF). The two types of media were used
in combination with keratinocyte serum-free medium (K-SFM)
supplemented with 25 mg per mL bovine pituitary extract (BPE), 0.2
ng per mL recombinant epidermal growth factor (rEGF), and 100 U
per mL penicillin and 100 mg per mL streptomycin and 2 mM L-
glutamine. Cells were incubated at 371C in a 5% CO2 atmosphere
with medium replenished every third day. Contaminating fibro-
blasts, when present, were eliminated by treating the cultures with
150 mg per mL geneticin sulfate (G418) for cycles of 48 h (Halaban
and Alfano, 1984). Follicular keratinocytes were separated from
the HFM cultures by differential trypsinization. The identity of the
isolated cells was confirmed by immunophenotyping at passage 1
with the melanocyte-lineage specific marker NKI/beteb against
glycoprotein100 (gp100) (Vennegoor et al, 1988).
Hair follicle keratinocytes Hair follicle keratinocytes (HFK) were
established by preparing single cell suspensions from isolated hair
follicles as described above. At the primary culture stage HFM
were selectively trypsinized from the culture. This process was
carried out under microscopic observation, the detached HFM
were placed into separate cell culture dishes, leaving behind an
essentially pure population of HFK, the follicular keratinocytes were
subsequently switched to K-SFM medium alone, which does not
support melanocyte growth.
Follicular papilla ﬁbroblasts Follicular papilla (FP) fibroblasts
were isolated using a simplified method recently described by
Magerl et al (2002). Briefly, anagen hair follicles were isolated by
micro-dissection from normal human haired scalp tissue from five
females after elective plastic surgery (ranging in age from 43 to 62
y, with a mean age of 50 y). Briefly, the hair follicles were gripped
1Park H, Gasparino J, Gilchrest BA: MITF regulates PKC-b
transcription. J Invest Dermatol 120:1157, 2003 (abstract).
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gently at the suprabulbar region using fine forceps. A gentle
closing pressure was applied and the connective tissue sheath
was then cut at the level of the stalk. This procedure resulted in the
externalization of the intact FP from the bulb into the dish. The cells
were incubated with RPMI 1640 medium supplemented with 10%
FCS, 100 U per mL penicillin, 100 mg per mL streptomycin and 2
mM L-glutamine at 371C in a 5% CO2 atmosphere. Culture medium
was replenished every third day once cell migration was evident.
All cell types (follicular melanocytes, keratinocytes, and FP
fibroblasts) were maintained in medium without FCS or BPE 48 h
prior to all experiments. This treatment was necessary to ensure
the removal of all exogenous sources of POMC peptides as the
half-lives of a-MSH, ACTH (Eberle, 1988), and b-END (Morch and
Pedersen, 1995) are less than 60 min.
Isolation of RNA Total RNA was isolated from detached follicular
melanocytes, keratinocytes, and FP fibroblasts by the guanidinium
thiocyanate–phenol—chloroform-based method, using Tri-Re-
agent (Sigma, Poole, Dorset, UK) according to the manufacturer’s
instructions. Total RNA isolated from HFM was subsequently
purified using Dynabeads mRNA direct kit (Dynal AS, Oslo,
Norway) according to the manufacturer’s instructions. This addi-
tional purification step was necessary to remove traces of melanin,
which can be inhibitory to the PCR reaction (Eckhart et al, 2000). To
avoid possible contamination of genomic DNA, extracted total
RNA samples were additionally treated with deoxyribonuclease I,
amplification grade (Invitrogen Ltd, Paisley, Scotland) according to
the manufacturer’s instructions.
RT-PCR The synthesis of cDNA was performed using RevertAid
M-MuLV RT (MBI Fermentas, Lithuania) according to the manu-
facturer’s instructions using 2 mg of total RNA or 0.2 mg of mRNA
and oligo (dT)18 and random hexamer primers (Sigma Genosys,
Pampisford, Cambridgeshire, UK). All PCR reagents were obtained
from MBI Fermentas (Vilnius, Lithuania) unless otherwise stated.
POMC was amplified using primer sets as described by
Slominski et al (1995) using a modified protocol as follows: one
cycle at 941C for 5 min; 35 cycles at 941C for 1 min, 671C for 1 min,
721C for 1 min; and a final cycle at 941C for 1 min, 671C for 1 min,
721C for 10 min. m-Opiate R was amplified using primer sets and
PCR parameters as described by Bigliardi et al (1998). Plasmid
containing POMC gene (gift from Dr J. Ancans, University of Riga,
Latvia) was used as a positive control for POMC mRNA expression.
Epidermal keratinocytes (EK) were used as a positive control cell
line for m-opiate R mRNA expression. RNA samples that were not
reverse transcribed and the omission of cDNA from the reaction
mixture served as negative controls.
Amplifications were performed using the Hybaid PCR sprint
temperature cycling system (Hybaid, Ashford, Middlesex, UK).
After amplification, 10 mL of the reaction mixture was mixed with
4 mL of gel loading solution (MBI Fermentas, Lithuania) and loaded
directly onto a 1.5% agarose gel (Sigma, Poole, Dorset, UK) con-
taining 1 mg per mL of EtBr (Sigma, Poole, Dorset, UK). A 100 base
pair (bp) DNA ladder (New England Biolabs, Hitchin, Hertfordshire,
UK) was also loaded followed by electrophoresis at a constant
voltage of 100 V using  0.5 tris–borate buffer. Gels were photo-
documented using the UVitec gel documentation system (UVitec
Limited, Cambridge, UK).
Immunohistochemistry Normal human haired scalp tissue was
obtained after elective plastic surgery (from five females, age range
43–60 y, mean age 50 y) or from occipital scalp tissue of two
normal healthy males (age 23 and 36 y). Seven mm thick
cryosections were cut and processed for double immunolabelling
as previously described (Kauser et al, 2003). Briefly, air-dried
sections were fixed in ice-cold acetone and blocked in 10% normal
donkey serum in PBS for 90 min at RT. Thereafter, sections were
incubated with either a primary antibody against b-END (1:10;
Biogenesis, Poole, Dorset, UK) or m-opiate R (1:100; Gramsch
Laboratories, Schwabhausen, Germany) at 41C for 18 h. Second-
ary antibody incubations were with either a rhodamine or
fluorescein-conjugated donkey anti-mouse or anti-rabbit second-
ary antibody (1:50; Jackson Immunoresearch laboratories, Inc.,
West Grove, Pennsylvania), for 60 min at RT. For the detection of
the melanocyte lineage-specific marker gp100, sections were
further blocked with 10% normal donkey serum and incubated
with the second primary antibody, NKI/beteb (1:30; Monosan,
Uden, Netherlands), for 2 h at RT and subsequently incubated with
a rhodamine or fluorescein-conjugated donkey anti-mouse sec-
ondary antibody (Jackson Immunoresearch laboratories, Inc., West
Grove) for 60 min at RT. Sections were washed in PBS and mounted
in Vectashield mounting medium with 40,6-diamidino-2-phenylin-
dole (DAPI) (Vector Laboratories Ltd, Peterborough, UK). The
omission of both primary antibodies, but the inclusion of secondary
antibodies, served as negative controls. The resulting staining was
visualized with a Leica DMIRB/E fluorescence microscope (Leica,
Wetzlar, Germany) and photo-documented with the aid of a
computer-assisted 3-CCD color video camera (Optivision, Ossett,
West Yorkshire, UK) and the Image Grabber PCI graphics program
(Neotech Ltd, Eastleigh, Hampshire, UK). The images produced
with the two different fluorochromes rhodamine (red) and fluor-
escein (green) were subsequently merged together using the Paint
Shop Pro 7 graphics program (JascSoftware, Oxon, UK). Co-
localization of b-END and m-opiate R with gp100-positive HFM was
indicated by the production of a yellow/orange color.
Frozen sections of human haired skin and murine heart (positive
control) were also incubated with a primary antibody against the
d-opiate receptor (d-opiate R) (1:1000; Gramsch Laboratories,
Schwabhausen, Germany) at 41C for 18 h. Subsequent steps in
immunostaining were performed using the DAKO LSAB2 HRP kit
and DAKO AEC substrate system (DAKO, Carpinteria, California)
according to the manufacturer’s instructions.
Immunocytochemistry For staining of cultured follicular melano-
cytes, keratinocytes, and FP fibroblasts (passage 2–5), cells were
seeded into eight-well Lab-Tek chamber slides (ICN Biomedicals,
Inc., Aurora, Ohio) at a density of 5000 cells per well and cultured
for 2–3 d. HFM primary cultures were also used as these cultures
contained distinct melanocyte sub-populations, including highly
proliferative amelanotic melanocytes that co-exist with intensely
pigmented but non-proliferative melanocytes (Tobin and Bystryn,
1996). Pigmented bulbar melanocytes are not usually retained in
culture after passage 2, the only cells remaining are the initially
amelanotic cells. Furthermore, not only do these cells proliferate
more rapidly compared with pigmented EM, amelanotic HFM
continue to divide for a greater number of passages (Tobin and
Bystryn, 1996).
FCS and BPE were omitted from the culture media 48 h prior to
immunostaining. Cells were rinsed briefly in PBS for 5 min and then
fixed in ice-cold methanol for 10 min at -201C. Cells were blocked
in 10% normal goat or donkey serum (for the staining of primary
follicular melanocyte cultures), rinsed briefly in PBS and incubated
with b-END (1:10), m-opiate R (1:100), and d-opiate R (1:1000)
specific antibodies at 41C for 18 h. Subsequent steps in
immunostaining were performed using the DAKO LSAB2 HRP kit
and DAKO AEC substrate system (DAKO, Carpinteria, California)
according to the manufacturer’s instructions or by indirect immuno-
fluorecence as described above.
Assessment of melanin content, dendricity, and cell prolifer-
ation Melanocyte cultures were grown without FCS and BPE for
48 h prior to stimulation with 108 M b-END (Sigma, Poole, Dorset,
UK) for 72 h. HFM cultures that were established in TPA/CT
supplemented medium were switched to bFGF/ET-1 supplemen-
ted medium for 8 d prior to stimulation experiments (this 8-d
period may not be long enough however, to remove all residual
effects of these artificial mitogens). For stimulation 108 M b-END
was chosen, as the greatest effects on melanogenesis, dendricity,
and proliferation were seen at this concentration during preliminary
experiments compared with 106 and 1010 M. Melanocytes from
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the same donor were maintained in parallel in the absence of the
peptide and served as a negative control.
For the assessment of melanocyte dendricity, cells were
photographed 72 h after b-END stimulation. Representative
photographs were taken from up to eight random and different
fields each incorporating approximately 10 cells for each cell line
and the number of cells with greater than three dendrites was
counted and compared with controls. The cells were subsequently
trypsinized and counted using a Neubauer counting chamber.
Melanocytes were pelleted by centrifugation and solubilized in 1 M
sodium hydroxide, boiled and melanin content measured spectro-
photometrically at 475 nm. A standard curve of synthetic melanin
(Sigma, Poole, Dorset, UK) was the basis for melanin content
determination. Both melanin content and cell counts were
determined at least three times for each cell line examined and
average values were taken. Results were determined as pg
melanin per cell and expressed as percentage increase in melanin
content above control unstimulated cells. The increase in cell
number was expressed as percentage increase in cell number
above control unstimulated levels.
Immunogold transmission electron microscopy Melanocyte
cultures (passage 3–5) were processed for post-embedding immuno-
electron microscopy as described elsewhere (Kauser et al,
2003). FCS and BPE were removed from the melanocyte culture
medium 48 h prior to experiments. Briefly, cells were trypsinized,
pelleted by gentle centrifugation and fixed in 0.5% glutaraldehyde
(Agar Scientific, Stanstead, Essex, UK) and 2% paraformaldehyde
(Sigma, Poole, Dorset, UK). The fixed cells were pelleted through
1% low melting point agarose (Bio-Rad Laboratories, Hercules,
California), dehydrated in graded series of ethanol. Blocks were
infiltrated with hydrophillic Unicryl resin (British BioCell Interna-
tional, Cardiff, Wales, UK) followed by polymerization using UV
light (360 nm).
Ultrathin sections (90 nm) were cut using a Reichert-Jung
ultramicrotome (Vienna, Austria), mounted on 200 mesh nickel
grids coated with carbon (Agar Scientific, Stanstead, Essex, UK)
and blocked in 10% normal goat serum and 2% bovine serum
albumin (BSA) in PBS (pH 8.2) for 1 h. Sections were incubated
with the primary antibodies against b-END (neat) or m-opiate R
(1:100) for 18 h at 41C. This was followed by incubation with the
secondary goat anti-rabbit or anti-mouse antibody (1:60) con-
jugated to 10 nm gold particles (British BioCell International,
Cardiff, Wales, UK) for 1 h at RT. Sections were washed in PBS
containing 2% BSA (pH 8.2) between each step, rinsed in distilled
water and lightly counterstained with 2% uranyl acetate and
Reynold’s lead citrate solution. The cells were examined and
photographed using a Jeol 1200 EX transmission electron
microscope (Jeol, Tokyo, Japan).
Statistical analysis Statistical significance was assessed using
Student’s paired t test.
This work was supported by a grant to DJT from Procter and Gamble
Ltd, Surrey, UK.
DOI: 10.1111/j.0022-202X.2004.22724.x
Manuscript received August 12, 2003; revised January 12, 2004;
accepted for publication February 16, 2004
Address correspondence to: Dr Desmond J Tobin, Department of
Biomedical Sciences, University of Bradford, Bradford, West Yorkshire
BD7 1DP, UK. Email: dtobin@bradford.ac.uk
References
Al Rustom K, Gerard J, Pierard GE: Extrapituitary neuroendocrine melanoderma.
Unique association of extensive melanoderma with macromelanosomes
and extrapituitary secretion of a high molecular weight neuropeptide
related to pro-opiomelanocortin. Dermatologica 173:157–162, 1986
Belcheva MM, Szucs M, Wang D, Sadee W, Coscia CJ: Mu-opioid receptor-
mediated ERK activation involves calmodulin-dependent epidermal
growth factor receptor transactivation. J Biol Chem 276:33847–33853,
2001
Belon PE: UVA exposure and pituitary secretion. Variations of human lipotropin
concentrations (beta LPH) after UVA exposure. Photochem Photobiol
42:327–329, 1985
Benjannet S, Rondeau N, Day R, Chretien M, Seidah NG: PC1 and PC2 are
proprotein convertases capable of cleaving proopiomelanocortin at
distinct pairs of basic residues. Proc Natl Acad Sci USA 88:3564–3568,
1991
Bennett DC, Bridges K, McKay IA: Clonal separation of mature melanocytes from
premelanocytes in a diploid human cell strain: Spontaneous and induced
pigmentation of premelanocytes. J Cell Sci 77:167–183, 1985
Bigliardi PL, Bigliardi-Qi M, Buechner S, Rufli T: Expression of mu-opiate receptor
in human epidermis and keratinocytes. J Invest Dermatol 111:297–301,
1998
Bigliardi-Qi M, Bigliardi PL, Eberle AN, Buchner S, Rufli T: Beta-endorphin
stimulates cytokeratin 16 expression and downregulates mu-opiate
receptor expression in human epidermis. J Invest Dermatol 114:527–
532, 2000
Bigliardi PL, Buchner S, Rufli T, Bigliardi-Qi M: Specific stimulation of migration of
human keratinocytes by mu-opiate receptor agonists. J Recept Signal
Transduct Res 22:191–199, 2002
Botchkarev VA, Botchkareva NV, Slominski A, Roloff B, Luger T, Paus R:
Developmentally regulated expression of alpha-MSH and MC-1 receptor
in C57BL/6 mouse skin suggests functions beyond pigmentation. Ann NY
Acad Sci 885:433–439, 1999
Burbach JPH, Weigant VM: Gene expression, biosynthesis and processing of
pro-opiomelanocortin derived and vasopressin. In: De weid D (ed).
Neuropeptides: Basics and Perspectives. Amsterdam: Elsevier; p 45–103,
1990
Burchill SA, Thody AJ: Melanocyte-stimulating hormone and the regulation
of tyrosinase activity in hair follicular melanocytes of the mouse.
J Endocrinol 111:225–232, 1986
Burchill SA, Virden R, Thody AJ: Regulation of tyrosinase synthesis and its
processing in the hair follicular melanocytes of the mouse during
eumelanogenesis and phaeomelanogenesis. J Invest Dermatol 93:236–
240, 1989
Busca R, Ballotti R: Cyclic AMP a key messenger in the regulation of skin
pigmentation. Pigment Cell Res 13:60–69, 2000
Chakraborty AK, Orlow SJ, Bolognia JL, Pawelek JM: Structural/functional
relationships between internal and external MSH receptors: Modulation
of expression in Cloudman melanoma cells by UVB radiation. J Cell
Physiol 147:1–6, 1991
Eberle AN: The Melanotropins: Chemistry, Physiology and Mechanisms of action.
Basel: Karger, 1988
Eckhart L, Bach J, Ban J, Tschachler E: Melanin binds reversibly to thermostable
DNA polymerase and inhibits its activity. Biochem Biophys Res Commun
271:726–730, 2000
Friedmann PS, Wren F, Buffey J, Macneil S: Alpha-MSH causes a small rise in
cAMP but has no effect on basal or ultraviolet-stimulated melanogenesis
in human melanocytes. Br J Dermatol 123:145–151, 1990
Furkert J, Klug U, Slominski A, Eichmuller S, Mehlis B, Kertscher U, Paus R:
Identification and measurement of beta-endorphin levels in the skin
during induced hair growth in mice. Biochim Biophys Acta 1336:315–322,
1997
Gilmore W, Weiner LP: The opioid specificity of beta-endorphin enhancement of
murine lymphocyte proliferation. Immunopharmacology 17:19–30, 1989
Halaban R, Alfano FD: Selective elimination of fibroblasts from cultures of normal
human melanocytes. In Vitro 20:447–450, 1984
Halaban R, Pomerantz SH, Marshall S, Lambert DT, Lerner AB: Regulation of
tyrosinase in human melanocytes grown in culture. J Cell Biol 97:
480–488, 1983
Holbrook KA, Hennings H: Phenotypic expression of epidermal cells in vitro: A
review. J Invest Dermatol 81:11s–24s, 1983
Horikawa T, Norris DA, Johnson TW, et al: DOPA-negative melanocytes in the
outer root sheath of human hair follicles express premelanosomal antigens
but not a melanosomal antigen or the melanosome-associated glycopro-
teins tyrosinase, TRP-1, and TRP-2. J Invest Dermatol 106:28–35, 1996
Hunt G, Donatien PD, Lunec J, Todd C, Kyne S, Thody AJ: Cultured human
melanocytes respond to MSH peptides and ACTH. Pigment Cell Res
7:217–221, 1994c
Hunt G, Todd C, Cresswell JE, Thody AJ: Alpha-melanocyte stimulating hormone
and its analogue Nle4DPhe7 alpha-MSH affect morphology, tyrosinase
194 KAUSER ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
activity and melanogenesis in cultured human melanocytes. J Cell Sci
107:205–211, 1994a
Hunt G, Todd C, Kyne S, Thody AJ: ACTH stimulates melanogenesis in cultured
human melanocytes. J Endocrinol 140:R1–R3, 1994b
Hunt G, Todd C, Thody AJ: Unresponsiveness of human epidermal melanocytes
to melanocyte-stimulating hormone and its association with red hair. Mol
Cell Endocrinol 116:131–136, 1996
Kauser S, Schallreuter KU, Thody AJ, Gummer C, Tobin DJ: Regulation of human
epidermal melanocyte biology by beta-endorphin. J Invest Dermatol
120:1073–1080, 2003
Kieffer BL: Recent advances in molecular recognition and signal transduction of
active peptides: Receptors for opioid peptides. Cell Mol Neurobiol
15:615–635, 1995
Lee YS, Yuspa SH, Dlugosz AA: Differentiation of cultured human epidermal
keratinocytes at high cell densities is mediated by endogenous activation
of the protein kinase C signaling pathway. J Invest Dermatol 111:762–
766, 1998
Lerner AB, McGuire JS: Melanocyte-stimulating hormone and adrenocortico-
trophic hormone: Their relation to pigmentation. N Eng J Med 270:539–
546, 1964
Lerner AB, Moellmann G, Varga VL, Halaban R, Pawelek JM: Action of
melanocyte-stimulating hormone on pigment cells. Cold Spring Harbour
ConfCell Prolif 6:187–197, 1979
Levins PC, Carr DB, Fisher JE, Momtaz K, Parrish JA: Plasma beta-endorphin
and beta-lipoprotein response to ultraviolet radiation. Lancet 2:166,
1983
Liu JG, Anand KJ: Protein kinases modulate the cellular adaptations associated
with opioid tolerance and dependence. Brain Res Brain Res Rev 38:1–19,
2001
Lohmar P, Li CH: Biological properties of ovine beta-lipotropic hormone.
Endocrinology 82:898–904, 1968
Lunec J, Pieron C, Thody AJ: MSH receptor expression and the relationship to
melanogenesis and metastatic activity in B16 melanoma. Melanoma Res
2:5–12, 1992
Magerl M, Kauser S, Paus R, Tobin DJ: Simple and rapid method to isolate and
culture follicular papillae from human scalp hair follicles. Exp Dermatol
11:381–385, 2002
Mayer P, Tischmeyer H, Jayasinghe M, Bonnekoh B, Gollnick H, Teschemacher
H, Hollt V: A delta opioid receptor lacking the third cytoplasmic loop is
generated by atypical mRNA processing in human malignomas. FEBS
Lett 480:156–160, 2000
Morch H, Pedersen BK: Beta-endorphin and the immune system–possible role in
autoimmune diseases. Autoimmunity 21:161–171, 1995
Olson GA, Olson RD, Kastin AJ: Endogenous opiates: 1985. Peptides 7:907–933,
1986
Orlow SJ, Hotchkiss S, Pawelek JM: Internal binding sites for MSH: Analyses in
wild-type and variant Cloudman melanoma cells. J Cell Physiol 142:
129–136, 1990
Park H, Gonzalez S, Lee J, Middelkamp-Hup M, Kaposi S, Peterson S, Gilchrest
B: Topical application of a PKC inhibitor reduces length and thickness of
hair pigmentation. J Invest Dermatol 122:159–166, 2004
Park HY, Russakovsky V, Ohno S, Gilchrest BA: The beta isoform of protein
kinase C stimulates human melanogenesis by activating tyrosinase in
pigment cells. J Biol Chem 268:11742–11749, 1993
Persson AI, Thorlin T, Bull C, Eriksson PS: Opioid-induced proliferation through
the MAPK pathway in cultures of adult hippocampal progenitors. Mol Cell
Neurosci 23:360–372, 2003
Peters EM, Tobin DJ, Seidah NG, Schallreuter KU: Pro-opiomelanocortin-related
peptides, prohormone convertases 1 and 2 and the regulatory peptide
7B2 are present in melanosomes of human melanocytes. J Invest
Dermatol 114:430–437, 2000
Ranson M, Posen S, Mason RS: Human melanocytes as a target tissue for
hormones: In vitro studies with 1 alpha-25, dihydroxyvitamin D3, alpha-
melanocyte stimulating hormone, and beta-estradiol. J Invest Dermatol
91:593–598, 1988
Ruutiainen K, Erkkola R, Irjala K: Beta-endorphin basal levels in hirsute women.
Eur J Obstet Gynecol Reprod Biol 20:373–380, 1985
Schiller M, Raghunath M, Kubitscheck U, et al: Human dermal fibroblasts express
prohormone convertases 1 and 2 and produce proopiomelanocortin-
derived peptides. J Invest Dermatol 117:227–235, 2001
Seidah NG, Chretien M, Day R: The family of subtilisin/kexin like pro-protein and
pro-hormone convertases: Divergent or shared functions. Biochimie
76:197–209, 1994
Slominski A, Botchkareva NV, Botchkarev VA, Chakraborty A, Luger T, Uenalan
M, Paus R: ACTH production in C57BL/6 mouse skin. Ann NY Acad Sci
885:448–450, 1999
Slominski A, Ermak G, Hwang J, Chakraborty A, Mazurkiewicz JE, Mihm M:
Proopiomelanocortin, corticotropin releasing hormone and corticotropin
releasing hormone receptor genes are expressed in human skin. FEBS
Lett 374:113–116, 1995
Slominski A, Ermak G, Hwang J, Mazurkiewicz J, Corliss D, Eastman A: The
expression of proopiomelanocortin (POMC) and of corticotropin releasing
hormone receptor (CRH-R) genes in mouse skin. Biochim Biophys Acta
1289:247–251, 1996
Slominski A, Paus R, Mazurkiewicz J: Proopiomelanocortin expression in the skin
during induced hair growth in mice. Experientia 48:50–54, 1992
Slominski A, Wortsman J: Neuroendocrinology of the skin. Endocr Rev 21:
457–487, 2000a
Slominski A, Wortsman J, Luger T, Paus R, Solomon S: Corticotropin releasing
hormone and proopiomelanocortin involvement in the cutaneous re-
sponse to stress. Physiol Rev 80:979–1020, 2000b
Slominski A, Wortsman J, Mazurkiewicz JE, et al: Detection of proopiomelano-
cortin-derived antigens in normal and pathologic human skin. J Lab Clin
Med 122:658–666, 1993
Stenn KS, Paus R: Controls of hair follicle cycling. Physiol Rev 81:449–494,
2001
Suzuki I, Cone RD, Im S, Nordlund J, Abdel-Malek ZA: Binding of melanotropic
hormones to the melanocortin receptor MC1R on human melanocytes
stimulates proliferation and melanogenesis. Endocrinology 137:1627–1633,
1996
Takada K, Sugiyama K, Yamamoto I, Oba K, Takeuchi T: Presence of amelanotic
melanocytes within the outer root sheath in senile white hair. J Invest
Dermatol 99:629–633, 1992
Thody AJ, Ridley K, Penny RJ, Chalmers R, Fisher C, Shuster S: MSH peptides
are present in mammalian skin. Peptides 4:813–816, 1983
Tobin DJ, Bystryn JC: Different populations of melanocytes are present in hair
follicles and epidermis. Pigment Cell Res 9:304–310, 1996
Tobin DJ, Colen SR, Bystryn JC: Isolation and long-term culture of human hair-
follicle melanocytes. J Invest Dermatol 104:86–89, 1995
Tobin DJ, Gunin A, Magerl M, Handijski B, Paus R: Plasticity and cytokinetic
dynamics of the hair follicle mesenchyme: Implications for hair growth
control. J Invest Dermatol 120:895–904, 2003
Tobin DJ, Paus R: Graying: Gerontobiology of the hair follicle pigmentary unit.
Exp Gerontol 36:29–54, 2001
Tsatmali M, Wakamatsu K, Graham AJ, Thody AJ: Skin POMC peptides. Their
binding affinities and activation of the human MC1 receptor. Ann NY Acad
Sci 885:466–469, 1999
Vennegoor C, Hageman P, Van Nouhuijs H, Ruiter DJ, Calafat J, Ringens PJ,
Rumke P: A monoclonal antibody specific for cells of the melanocyte
lineage. Am J Pathol 130:179–192, 1988
Wakamatsu K, Graham A, Cook D, Thody AJ: Characterisation of ACTH peptides
in human skin and their activation of the melanocortin-1 receptor.
Pigment Cell Res 10:288–297, 1997
Wintzen M, Gilchrest BA: Proopiomelanocortin, its derived peptides, and the skin.
J Invest Dermatol 106:3–10, 1996
Wintzen M, Ostijn DM, Polderman MC, le Cessie S, Burbach JP, Vermeer BJ:
Total body exposure to ultraviolet radiation does not influence plasma
levels of immunoreactive beta-endorphin in man. Photodermatol Photo-
immunol Photomed 17:256–260, 2001a
Wintzen M, de Winter S, Out-Luiting JJ, van Duinen SG, Vermeer BJ: Presence of
immunoreactive beta-endorphin in human skin. Exp Dermatol 10:305–311,
2001b
Wu Y, McLaughlin PJ, Zagon IS: Ontogeny of the opioid growth factor, [Met5]-
enkephalin, preproenkephalin gene expression, and the zeta opioid
receptor in the developing and adult aorta of rat. Dev Dyn 211:327–337,
1998
Zagon IS, Wu Y, McLaughlin PJ: The opioid growth factor, [Met5]-enkephalin, and
the zeta opioid receptor are present in human and mouse skin and
tonically act to inhibit DNA synthesis in the epidermis. J Invest Dermatol
106:490–497, 1996
b-ENDORPHIN––REGULATOR OF HUMAN HAIR FOLLICLE MELANOCYTE BIOLOGY 195123 : 1 JULY 2004
